logo

Timothy Cloughesy, MD

Timothy Cloughesy, MD

Neurology Los Angeles, CA

Professor of Neuology/Director, UCLA NeuroOncology Program

Office Address

Office Map
  • 300 UCLA Medical Plaza
    Suite B200
    Los Angeles, CA 90095
    Phone: (310) 825-5321
    Fax: (310) 825-0644

Dr. Cloughesy's Clinical Specialties & Interests

  • Neurology: Neurooncology

Dr. Cloughesy's Education & Medical Training

  • UCLA Medical CenterUCLA Medical CenterResidency, Neurology
  • Maricopa Medical CenterMaricopa Medical CenterResidency, Internal Medicine
  • Tulane Univ Sch of MedTulane University School of MedicineMedical School

Dr. Cloughesy's Certifications & Licensure

  • CA State Medical LicenseCA State Medical License1988 - 2014
  • American Board of Psychiatry and NeurologyAmerican Board of Psychiatry and NeurologyNeurology, 1993

Dr. Cloughesy's Awards, Honors, & Recognition

  • SuperDoctors.comSuper DoctorSuperDoctors.com

Dr. Cloughesy's Clinical Trials

Dr. Cloughesy's Publications & Presentations

PubMed | Citations by Web of Science®

Grant Support

  • UCLA IRB 08-09-042: Phase I Trial Of Aflibercept (Vegf Trap) With Radiation The
    UCLA IRB 08-09-042: Phase I Trial Of Aflibercept (Vegf Trap) With Radiation TheNational Center For Research Resources
    2010 - 2010
  • UCLA IRB # 06-04-104 "A Phase I/II, Dual-Center, Open-Label Trial Of The SAFE
    UCLA IRB # 06-04-104 "A Phase I/II, Dual-Center, Open-Label Trial Of The SAFENational Center For Research Resources
    2009 - 2010
  • Phase II Single Arm Trial Of VEGF TRAP In Patients With Recurrent Temozolomide-
    Phase II Single Arm Trial Of VEGF TRAP In Patients With Recurrent Temozolomide-National Center For Research Resources
    2009 - 2009
  • Clinical Trial: A Phase II Trial Of Poly-Iclc In Patients With Recurrent Anaplas
    Clinical Trial: A Phase II Trial Of Poly-Iclc In Patients With Recurrent AnaplasNational Center For Research Resources
    2008 - 2008
  • Recurrent Temozolomide-Resistant Malignant Gliomas
    Recurrent Temozolomide-Resistant Malignant GliomasNational Center For Research Resources
    2008 - 2008
  • "A Phase I/II Studies Of BAY 43-9006 (SORAFENIB) In Combin
    "A Phase I/II Studies Of BAY 43-9006 (SORAFENIB) In CombinNational Center For Research Resources
    2008 - 2008
  • UCLA IRB #05-12-061 "A Phase I Study Of Vorinostat (Suberoylanilide Hydroxami
    UCLA IRB #05-12-061 "A Phase I Study Of Vorinostat (Suberoylanilide HydroxamiNational Center For Research Resources
    2007 - 2009
  • UCLA IRB (PENDING) "A Phase I/II Studies Of BAY 43-9006 (SORAFENIB) In Combin
    UCLA IRB (PENDING) "A Phase I/II Studies Of BAY 43-9006 (SORAFENIB) In CombinNational Center For Research Resources
    2007 - 2009
  • Phase I/II Study Of OSI-774 (ERLOTINIB) And CCI-779 (TEMSIROLIMUS) In Patient
    Phase I/II Study Of OSI-774 (ERLOTINIB) And CCI-779 (TEMSIROLIMUS) In PatientNational Center For Research Resources
    2007 - 2010
  • A Biomarker And Phase II Study Of GW 572016 In Recurrent Malignant Glioma (Na
    A Biomarker And Phase II Study Of GW 572016 In Recurrent Malignant Glioma (NaNational Center For Research Resources
    2007 - 2008
  • UCLA IRB # 06-04-016 "Phase II Trial Of Bevacizumab In Combination With Temoz
    UCLA IRB # 06-04-016 "Phase II Trial Of Bevacizumab In Combination With TemozNational Center For Research Resources
    2007 - 2010
  • Consortium Therapeutic Studies Of Primary Central Nervous System Malignancies
    Consortium Therapeutic Studies Of Primary Central Nervous System MalignanciesNational Cancer Institute
    2007 - 2008
  • A Multicenter, Open-Label, Randomized, Uncontrolled, Phase IIA Trial In Subje
    A Multicenter, Open-Label, Randomized, Uncontrolled, Phase IIA Trial In SubjeNational Center For Research Resources
    2006 - 2006
  • Phase II Trial Of EMD 121974 For Recurrent Glioblastoma: A Clinical Trial Wit
    Phase II Trial Of EMD 121974 For Recurrent Glioblastoma: A Clinical Trial WitNational Center For Research Resources
    2006 - 2007
  • A Phase I/II Trial Of OSI-774 In Patients With Recurrent Malignant Gliomas An
    A Phase I/II Trial Of OSI-774 In Patients With Recurrent Malignant Gliomas AnNational Center For Research Resources
    2005 - 2006
  • Consortium Therapeutic Studies Of Primary Central Nervi*
    Consortium Therapeutic Studies Of Primary Central Nervi*National Cancer Institute
    2005 - 2006
  • A Modified Phase I/II Trial Of Rapamycin In Patients With Malignant Gliomas
    A Modified Phase I/II Trial Of Rapamycin In Patients With Malignant GliomasNational Center For Research Resources
    2005 - 2006
  • Phase I-II Trial Of STI-571 (Nsc 716051) In Patients With Recurrent Malignant
    Phase I-II Trial Of STI-571 (Nsc 716051) In Patients With Recurrent MalignantNational Center For Research Resources
    2005 - 2005
  • Phase II Trial Of Poly-Iclc For Glioblastoma [Nabtc 01-05]
    Phase II Trial Of Poly-Iclc For Glioblastoma [Nabtc 01-05]National Center For Research Resources
    2005 - 2005
  • A Phase II Trial Of STI-571 ( NSC 716051) In Patients With Recurrent Meningio
    A Phase II Trial Of STI-571 ( NSC 716051) In Patients With Recurrent MeningioNational Center For Research Resources
    2005 - 2006
  • ZD1839 For Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or GLI
    ZD1839 For Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or GLINational Center For Research Resources
    2005 - 2006
  • A Phase II Trial Of Poly-Iclc In Patients With Recurrent Anaplastic Glioma  N
    A Phase II Trial Of Poly-Iclc In Patients With Recurrent Anaplastic Glioma NNational Center For Research Resources
    2005 - 2007
  • Phase I/II Of R115777 In Patients With Recurrent Malignant Gliomas
    Phase I/II Of R115777 In Patients With Recurrent Malignant GliomasNational Center For Research Resources
    2005 - 2005
  • Consortium Therapeutic Studies Of Primary Central Nervi*
    Consortium Therapeutic Studies Of Primary Central Nervi*National Center For Research Resources
    2005 - 2008
  • Quantified Gene Expression Improves Prognosis
    Quantified Gene Expression Improves PrognosisNational Center For Research Resources
    2004 - 2004
  • Phase II Evaluation Of Fenretinide (Nsc 374551) As A S
    Phase II Evaluation Of Fenretinide (Nsc 374551) As A SNational Center For Research Resources
    2004 - 2004
  • Phase I/II Trial Of OSI-774 In Patients With Recurrent
    Phase I/II Trial Of OSI-774 In Patients With RecurrentNational Center For Research Resources
    2004 - 2004
  • ZD1839 For Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Gli...
    ZD1839 For Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Gli...National Center For Research Resources
    2004 - 2004
  • Phase I/II Trial Of CCI-779 In Patients With Malignant Gliomas (Nabtc 01-01)
    Phase I/II Trial Of CCI-779 In Patients With Malignant Gliomas (Nabtc 01-01)National Center For Research Resources
    2004 - 2004
  • Phase I/II Of R115777 For Recurrent Malignant Gliomas
    Phase I/II Of R115777 For Recurrent Malignant GliomasNational Center For Research Resources
    2004 - 2004
  • Consortium Therapeutic Studies Of CNS Malignancies
    Consortium Therapeutic Studies Of CNS MalignanciesNational Cancer Institute
    2004 - 2004
  • Modified Phase I/II Trial Of Rapamycin In Patients Wit
    Modified Phase I/II Trial Of Rapamycin In Patients WitNational Center For Research Resources
    2004 - 2004
  • Phase I/II Trial Of Ironstecan In Patients With Glioma
    Phase I/II Trial Of Ironstecan In Patients With GliomaNational Center For Research Resources
    2001 - 2001
  • Phase 2 Trial Of Thymidine/Carboplatin Therapy Of Glioma
    Phase 2 Trial Of Thymidine/Carboplatin Therapy Of GliomaNational Center For Research Resources
    2001 - 2001
  • Gene Expression Prognosis &Trtmt Response Stratification In PATS W/ Glioma
    Gene Expression Prognosis &Trtmt Response Stratification In PATS W/ GliomaNational Center For Research Resources
    1999 - 2002
  • Quantify Gene Expression: Prognosis &Therapy Response Stratification In Glioma
    Quantify Gene Expression: Prognosis &Therapy Response Stratification In GliomaNational Center For Research Resources
    1998 - 1998

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • BCBS Blue Card PPO
  • BCBS California CaliforniaCare HMO
  • BCBS California PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • First Health PPO
  • Great West PPO
  • Health Net California Large Group PPO
  • Multiplan PHCS PPO
  • Multiplan PHCS PPO - Kaiser
  • Multiplan PPO
  • Pacificare HMO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO

Physicians, view Dr. Cloughesy's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV